Articles from INBRAIN Neuroelectronics

INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing graphene-based brain-computer interface (BCI) therapeutics, today announced the successful completion and results of MINIGRAPH (Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disorders), a European Innovation Council (EIC) funded project.

INBRAIN Neuroelectronics, a neurotechnology company developing graphene-based brain-computer interface therapeutics (BCI-Tx), today announced completion of patient recruitment in its first-in-human study evaluating its graphene cortical interface. A total of ten patients were recruited into its first-in-human study, and eight patients were treated surgically, with no perioperative device failure observed during use. Complete datasets were obtained from eight patients.

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the appointment of Scott Huennekens as Chairman of its Board of Directors. Mr. Huennekens joins the company as INBRAIN accelerates development of its next-generation graphene-based BCI therapeutics into pivotal trials and commercialization for neurological disorders.

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced a strategic collaboration with Microsoft to explore the use of agentic artificial intelligence (AI) powered by Microsoft’s cloud and data infrastructure to advance real-time precision neurology and next-generation brain-computer interface (BCI) therapeutics.

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced it has entered into a know-how collaboration agreement with Mayo Clinic. The collaboration seeks to accelerate the development and commercialization of INBRAIN’s precision BCI-Tx for patients with unmet needs in neurological-related disorders.

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. The round was led by imec.xpand with new investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Existing investors Asabys Partners, Aliath Bioventures and Vsquared also participated, bringing the total amount raised since inception to $68 million.

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company pioneering graphene-based neural technologies, announced today the world’s first human procedure of its cortical interface in a patient undergoing brain tumor resection. INBRAIN’s BCI technology was able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision.

INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The aim of the collaboration is to co-develop the next generation of graphene bioelectronic vagus nerve therapies targeting severe chronic diseases in Merck’s KGaA, Darmstadt, Germany therapeutic areas through INNERVIA Bioelectronics, a subsidiary of INBRAIN Neuroelectronics.